Recombinant antibody constructs in cancer therapy

Current Opinion in Immunology

Volumn 11, Issue 5, 1999, Pages 548-557

  Hudson, Peter J ^a  

^a University of Melbourne   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; DRUG; ENZYME; HYBRID PROTEIN; RADIOISOTOPE; RECOMBINANT ANTIBODY; TOXIN; VIRUS ANTIBODY; VIRUS VECTOR;

BIOSENSOR; CANCER; CANCER IMMUNOTHERAPY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; GENETIC ENGINEERING; HUMAN; NONHUMAN; REVIEW; T LYMPHOCYTE;

EID: 0032822839     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00013-8     Document Type: Review

References (87)

1. Farah RA, Clinchy B, Herrera L, Vitetta ES The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryot Gene Expr. 8:1998;321-345. This review is an excellent summary of the clinical applications using monoclonal antibodies and recombinant derivatives up to 1998.
2. Hudson PJ Recombinant antibody fragments. Curr Opin Biotechnol. 9:1998;395-402. This review summarises the highlights in recombinant antibody designs in 1997 and early 1998. A comparison with my current review here demonstrates the very rapid progress that has been made in the design and engineering of recombinant antibody fragments throughout 1998 and 1999.
3. Dall'Acqua W, Carter P Antibody engineering. Curr Opin Struct Biol. 8:1998;443-450.
4. Leget GA, Czuczman MS Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 10:1998;548-551. This publication reviews the pharmocokinetics and Phase I and II trials for the first FDA-approved recombinant cancer therapeutic antibody. The antibody was designed as a simple chimaera of mouse V-domains fused to human C-domains. In the pivotal study of Rituximab, an overall response rate of 50% was achieved with median time to progression in responders of 13.2 months. It is a useful reference for initial clinical data using recombinant antibodies and will be followed by many other publications in 1999 describing more detailed clinical trials with 'Rituxan' and other therapeutic recombinant antibodies.
5. Goldenberg MM Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 21:1999;309-318.
6. ••] and their successful screening methods against cell surface antigens are described in [76].
7. Bradbury A Display technologies expand their horizons. Trends Biotechnol. 17:1999;137-138.
8. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruine AP, Arends JW, Hoogenboom HR A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem. 274:1999;18218-18230. This is probably the largest naïve Fab library constructed to date. Refer to World Wide Web sites listed in [82-87] for descriptions of other antibody libraries that are commercially available.
9. Ridgway JB, Ng E, Kern JA, Lee J, Brush J, Goddard A, Carter P Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines. Cancer Res. 59:1999;2718-2723.
10. Muller KM, Arndt KM, Pluckthun A Model and simulation of multivalent binding to fixed ligands. Anal Biochem. 261:1998;149-157.
11. Roux KH, Strelets L, Brekke OH, Sandlie I, Michaelsen TE Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. J Immunol. 161:1998;4083-4090.
12. Hewat EA, Marlovits TC, Blaas D Structure of a neutralizing antibody bound monovalently to human rhinovirus 2. J Virol. 72:1998;4396-4402.
13. Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA. 94:1997;7509-7514.
14. Colcher D, Pavlinkova G, Beresford G, Booth BJM, Choudhury A, Batra SK Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med. 42:1998;225-241. An excellent review describing the practical limitations of large (150 kDa) IgGs resulting from slow clearance from the blood pool, poor diffusion from the vasculature and poor penetration through the tumour mass. Antibody valency and recombinant designs are also reviewed as are factors that are critical for the functional affinity of an antibody for a cell surface antigen or a polymeric antigen.
15. Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RHJ Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab fragments. Brit J Cancer. 1999;. in press.
16. Humphreys DP, Vetterlein OM, Chapman AP, King DJ, Antoniw P, Suitters AJ, Reeks DG, Parton TA, King LM, Smith BJet al. F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model. J Immunol Methods. 217:1998;1-10.
17. Atwell J, Breheney KA, Lawrence LJ, McCoy AJ, Kortt AA, Hudson PJ ScFv multimers: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng. 12:1999;597-604. This publication provides the first detailed description of the diabody → triabody transition and explains why scFv trimers are the preferred conformation when very short polypeptide linkers between V-domains prevent diabody formation.
18. LeGall F, Kipriyanov SM, Moldenhauer G, Little M Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on binding. FEBS Lett. 453:1999;164-168.
19. Beresford GW, Pavlinkova G, Booth BJ, Batra SK, Colcher D Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int J Cancer. 81:1999;911-917.
20. Lawrence LJ, Kortt AA, Iliades P, Tulloch PA, Hudson PJ Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett. 425:1998;479-484.
21. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58:1998;485-490.
22. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Brit J Cancer. 77:1998;1405-1412. This phage-selected and affinity-matured recombinant antibody may be the world's first phage-engineered scFv in clinical trials. There is an excellent discussion of multivalent antibody design and an explanation of the functional affinity (avidity) gains that are made via apparently reduced off-rates, which result from both multiple binding and rebinding to the target antigens.
23. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59:1999;347-352.
24. Wu AM, Williams LE, Zieran L, Padma A, Sherman M, Bebb GG, Odom-Maryon T, Wong JYC, Shively JE, Raubitschek AA Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumour Targeting. 4:1999;47-54.
25. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:1996;3055-3061.
26. Olafsen T, Rasmussen IB, Norderhaug L, Bruland OS, Sandlie I IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. Immunotechnology. 4:1998;141-153.
27. Pavlinkova G, Beresford G, Booth BJ, Batra SK, Colcher D Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. Nucl Med Biol. 26:1999;27-34.
28. Arano Y, Fujioka Y, Akizawa H, Ono M, Uehara T, Wakisaka K, Nakayama M, Sakahara H, Konishi J, Saji H Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res. 59:1999;128-134.
29. Chapman AP, Antoni P, Spitali M, West S, Stephens S, King DJ Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol. 17:1999;780-783.
30. Robert B, Dorvillius M, Buchegger F, Garambois V, Mani JC, Pugnieres M, Mach JP, Pelegrin A Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). Int J Cancer. 81:1999;285-291. This paper describes the design of high-avidity antibodies by targeting two adjacent epitopes on a single target antigen. These 'biparatopic' antibodies are similar to 'CRAbs', the chelating recombinant antibodies described in [31]. High avidity will require that both arms bind simultaneously without a significant loss of entropy.
31. Neri D, Momo M, Prospero T, Winter G High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol. 246:1995;367-373.
32. Bauer S, Renner C, Juwana JP, Held G, Ohnesorge S, Gerlach K, Pfreundschuh M Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res. 59:1999;1961-1965.
33. Manzke O, Berthold F, Huebel K, Tesch H, Diehl V, Bohlen H CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow. Int J Cancer. 80:1999;715-722.
34. Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber JS A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol Immunother. 48:1999;9-21.
35. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58:1998;5738-5748.
36. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol. 17:1999;181-186.
37. Kraeber-Bodere F, Faibre-Chauvet A, Sai-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thedrez P Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J Nucl Med. 40:1999;198-204.
38. H3 fusion proteins are forced to conjugate exclusively into bispecific heterodimers (minibodies).
39. Helfrich W, Kroesen BJ, Roovers RC, Westers L, Molema G, Hoogenboom HR, de Leij L Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer. 76:1998;232-239.
40. Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qinghua L, Wolf J, Diehl V, Cochet O, Winter G, Bohlen H Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res. 59:1999;2909-2916.
41. Kipriyanov SM, Moldenhauer G, Strauss G, Little M Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer. 77:1998;763-770.
42. Muller KM, Arndt KM, Pluckthun A A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett. 432:1998;45-49.
43. Chaudri ZN, Bartlet-Jones M, Panayotou G, Klonisch T, Roitt IM, Lund T, Delves PJ Dual specificity antibodies using a double-stranded oligonucleotide bridge. FEBS Lett. 450:1999;23-26.
44. Reiter Y, Pastan I Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 16:1998;513-520.
45. Tseng YL, Hong RL, Tao MH, Chang FH Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer. 80:1999;723-730.
46. Carter G, White P, Fernie M, King S, McLean G, Titball R, Carr FJ Enhanced antitumour effect of liposomal daunorubicin using antibody-phospholipase C conjugates or fusion protein. Int J Oncol. 13:1998;819-825. The authors describe a new two-step method for targeting cytotoxic drugs to tumour cells. Antibody-phospholipase-C fusion proteins first target cancer cells, then lyse drug-loaded liposomes for a cytotoxic effect localised at the tumour. This obviously has the capacity for massive drug-loading into the tumour.
47. Shabat D, Rader C, List B, Lerner RA, Barbas CF III Multiple event activation of a generic prodrug trigger by antibody catalysis. Proc Natl Acad Sci USA. 96:1999;6925-6930. This prodrug could possibly be incorporated into very useful ADEPT (antibody-directed enzyme-prodrug therapy) strategy using bispecific constructs. The antibody 'Abzyme' component catalyses cytotoxic activation across a wide range of drug-masking chemistries because it is compatible with virtually any heteroatom. The reaction cascade is not catalyzed by any known natural enzyme and can be applied to release of anticancer drugs such as doxorubicin and camptothecin.
48. 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug Chem. 10:1999;502-511.
49. Hudson AJ, Normand N, Ackroyd J, Akhtar S Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Int J Pharm. 182:1999;49-58.
50. Martin F, Neil S, Kupsch J, Maurice M, Cosset F, Collins M Retrovirus targeting by tropism restriction to melanoma cells. J Virol. 73:1999;6923-6929.
51. Poul MA, Marks JD Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol. 288:1999;203-211. A remarkable exploitation in which scFv-targeted bacteriophages bound mammalian cells expressing the growth factor receptor ErbB2 and then amazingly underwent receptor-mediated endocytosis. The scFv-targeted phages were isolated by selection from a phage antibody library on breast tumor cells and recovery of infectious phages from within the cell.
52. Chen J, Gamou S, Takayanagi A, Ohtake Y, Ohtsubo M, Shimizu N Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies: improved immunogene approach. Cancer Gene Ther. 5:1998;357-364.
53. Mezzanzanica D, Canevari S, Mazzoni A, Figini M, Colnaghi MI, Waks T, Schindler DG, Eshhar Z Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther. 5:1998;401-407.
54. Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, Parmiani G, Eshhar Z, Canevari S, Colombo MP Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 58:1998;4146-4154.
55. Peng LS, Penichet ML, Morrison SL A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol. 163:1999;250-258.
56. Timmerman JM, Levy R Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 50:1999;507-529.
57. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 5:1999;780-787.
58. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol. 17:1999;253-257. This paper is remarkable in that therapeutic delivery of the fusion protein was achieved as a DNA vaccine. This method is likely to become far more popular due to the simplicity of DNA transfection in vivo.
59. Tripathi PK, Qin H, Deng S, Xu C, Bhattacharya-Chatterjee M, Foon KA, Chatterjee SK Antigen mimicry by an anti-idiotype antibody single chain variable fragment. Mol Immunol. 35:1998;853-863.
60. Dougan DA, Malby RL, Gruen LC, Kortt AA, Hudson PJ Effects of substitutions in an antibody binding surface on antigen affinity. Prot Eng. 11:1998;65-74.
61. Braden BC, Goldman ER, Mariuzza RA, Poljak RJ Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3. Immunol Rev. 163:1998;45-57.
62. McCoy AJ, Epa VC, Colman PM Electrostatic complementarity at protein/protein interfaces. J Mol Biol. 268:1997;570-584.
63. Dokurno P, Bates PA, Band HA, Stewart LMD, Lally JM, Burchell JM, Taylor-Papadimitriou J, Snary D, Sternberg MJE, Freemont PS Crystal structure at 1.95 Å resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition. J Mol Biol. 284:1998;713-728.
64. Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S, Wyns L A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure. 7:1999;361-370.
65. Nuttall SD, Rousch MJM, Irving RA, Hufton SE, Hoogenboom HR, Hudson PJ Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides. Proteins. 36:1999;217-227. The first reported exploitation of a soluble humanised V-like domain to target clefts and canyons in enzymes, viral capsids and receptors; in this case the target was the G-protein-coupled somatostatin receptor.
66. Verma R, Boleti E, George ATJ Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Methods. 216:1998;165-181.
67. Worn A, Pluckthun A Different equilibrium stability behavior of scfv fragments: identification, classification, and improvement by protein engineering. Biochemistry. 38:1999;8739-8750.
68. Langedijk AC, Honegger A, Maat J, Planta RJ, van Schaik RC, Pluckthun A The nature of antibody heavy chain residue H6 strongly influences the stability of a VH domain lacking the disulfide bridge. J Mol Biol. 283:1998;95-110.
69. Almog O, Benhar I, Vasmatzis G, Tordova M, Lee B, Pastan I, Galliland G Crystal structure of the disulphide-stabilised Fv fragment of anticancer antibody B1. Proteins. 31:1998;128-138.
70. Jager M, Pluckthun A Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen. J Mol Biol. 285:1999;2005-2019.
71. Ramm K, Gehrig P, Pluckthun A Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J Mol Biol. 290:1999;535-546.
72. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 273:1998;21769-21776.
73. x. Proc Natl Acad Sci USA. 96:1999;6953-6958.
74. Hanes J, Jermutus L, Schaffitzel C, Pluckthun A Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems. FEBS Lett. 450:1999;105-110. The first detailed comparison on the use of prokaryotic versus eukaryotic ribosomes for the display of antibody-fragment repertoires. Both methods are efficient, with the authors preferring their own in-house prokaryotic system. Other groups have exploited the alternative eukaryotic ribosome methods (see [75]).
75. He M, Taussig MJ Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. 25:1997;5132-5134.
76. Hoogenboom HR, Lutgerink JT, Pelsers M, Rousch M, Coote J, van Neer N, de Bruine A, van Nieuwenhoven FA, Glatz JFC, Arends J-W Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library. Eur J Biochem. 260:1999;774-784.
77. Osbourn JK, Earnshaw JC, Johnson KS, Parmentier M, Timmermans V, McCafferty J Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library. Nat Biotechnol. 16:1998;778-781.
78. Daugherty PS, Chen G, Olsen MJ, Iverson BL, Georgiou G Antibody affinity maturation using bacterial surface display. Prot Eng. 11:1998;825-829. This method has the potential to replace phage display. The library selection systems are easy, using FACS, and the method can be adapted to mutator cells for rapid affinity maturation.
79. Spada S, Honegger A, Pluckthun A Reproducing the natural evolution of protein structural features with the selectively infective phage (SIP) technology. The kink in the first strand of antibody kappa domains. J Mol Biol. 283:1998;395-407.
80. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1999;1236-1243.
81. Borrebaeck CAK Human monoclonal antibodies: the emperor's new clothes? Nat Biotechnol. 17:1999;621.
82. The Recombinant Antibody Page on World Wide Web URL: http://www.mgen.uni-heidelberg.de/SD/SdscFvSite.html.
83. The V base database of human antibody genes on World Wide Web URL: http://www.mrc-cpe.cam.ac.uk/imt-doc.
84. The antibody Resource Page on World Wide Web URL: http://www.antibodyresource.com.
85. Index of articles by Pharma Biotech on World Wide Web URL: http://www.medicine-news.com.
86. Morphosys AG Combinatorial Biology in Drug Discovery on World Wide Web URL: http://www.morphosys.com/.
87. Cambridge Antibody Technology Group Therapeutic Products on World Wide Web URL: http://www.catplc.co.uk/.